ClinicalTrials.gg
Active, not recruitingNCT05578664PE-PEUpdated Oct 21, 2026

Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer

A Phase 2 interventional study of Pembrolizumab injection plus metastasis directed treatment (surgery or RT) and Tumor resection or RT in Oligometastatic Renal Cell Carcinoma, sponsored by Consorzio Oncotech. Active, not recruiting at 33 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Consorzio Oncotech · Phase 2, Interventional, and Treatment

How we know · 2 judgments

Updated Oct 21, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Carcinoma, Renal Cell with a site in Italy — 28 open to participants now, 47 under way, 15 of them phase 3. Carcinoma, Renal Cell · Italy.

Enrollment
89th of 123
85 · median 252
Started
2023
with 8 others
Phase 2
34 of 154
2 open now
Primary completion
2028-03
later than 34 of 46 live
Registered
123rd of 154
by date

Among the 154 studies in Carcinoma, Renal Cell with a site in Italy, this one is the 89th largest by enrollment of the 123 interventional ones that give a count, is one of 9 that started in 2023, is one of 34 in phase 2, reaches primary completion later than 34 of the 46 other live ones, and was the 123rd registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

28 of the 154 studies in Carcinoma, Renal Cell with a site in Italy are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Carcinoma, Renal Cell with a site in Italy, or all of them as a file.
02

Study summary

This is a phase II trial aiming at assessing the efficacy of pembrolizumab to delay tumor progression in patients with oligometastatic clear cell metastatic Renal Cell Carcinoma (mRCC).

Eligible patients for this trial should have received previous surgery for primary tumor and have maximum of three metastases considered eligible for radical therapy (surgery or metastases directed radiotherapy).

Eligible patients will be randomized 2:1 to receive:

  • ARM A: pembrolizumab at flat dose of 400 mg every six weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1; or
  • ARM B: local therapy alone within 42 days.
Read the detailed description

In this study, approximately 81 participants with ccRCC will be enrolled. The RESORT and E2810 clinical trials reported a rate of patients free of relapse of about 50% at 24 months. This study aims to improve this rate from 50% to 70% corresponding to an Hard Ratio of 0.51. Therefore, the sample size required for demonstrating this relapse-free survival (RFS) advantage includes a total of 74 patients that will be randomized 2:1 in the arm A or B respectively. The study will detect a treatment difference with the 80% probability at a one-sided p and 10.0% significance level, if the true hazard ratio is 0.51. This is based on the assumption that the accrual period will be 30 months, the follow up period will be 24 months, and the median RFS is 24 months.

Because 10% of dropout has been estimated, the final number of patients is 81.

03

Conditions studied

  • Oligometastatic Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male/female participants who are at least 18 years of age on the day of signing with confirmed diagnosis of clear cell renal cell carcinoma will be enrolled in this study.
  2. Have undergone a partial nephrectomy or radical complete nephrectomy with negative surgical margins.
  3. Evidence of oligo- disease eligible for local treatment with radiotherapy or surgery, defined as:

    1. Appearance of new metastases within 5 years from previous eradication of primary tumors or previous metastasectomy.
    2. Presence of maximum 3 metastases in the same site or in different sites with the exception of bone metastases that cannot exceed the number of 2 if they are the sole disease site or one in case of multiple sites.
    3. Each metastasis should be less than 3 cm in the maximum diameter and less than 5 cm in the sum of the longest tumor diameters (this evaluation should apply also for lymph nodes).
  4. Has received no prior systemic therapy for Renal Cell Carcinoma (RCC).
  5. Has (ECOG) performance status of 0 to 1 within 7 days of before the start of study intervention.
  6. The participant (or legally acceptable representative) has provided documented informed consent/assent for the study.
  7. Have provided sample or newly obtained core or excisional biopsy of a primary tumor or tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slide. Newly obtained biopsies are preferred to archived tissue.

    Female participants:

  8. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of (WOCBP) as defined in Appendix 3 of the Study protocol OR
    2. A WOCBP who agrees to follow the guidance in Appendix 3 during the treatment period and for at least 120 days (corresponding to time needed to eliminate any study treatment(s)) plus 30 days (a menstruation cycle) for study treatments with risk of genotoxicity after the last dose of study treatment.
  9. Adequate organ function defined as:

System - Laboratory Value

Hematological

  • (ANC): ≥ 1500/μl
  • : ≥ 100 000/μl
  • : ≥ 9.0 g/dL or ≥ 5.6 mmol/L

Renal

  • Creatinine: ≤1.5 x (ULN) OR
  • Measured or calculated : ≥ 30 mL/min for participant with creatinine levels > 1.5 x institutional ULN ( can also be used in place of creatinine or CrCl)

Hepatic

  • Total : ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels > 1.5 x ULN
  • (AST or SGOT) and alanine transaminase (ALT or SGPT): ≤ 2.5 x ULN (≤ 5 ULN for participants with liver metastases)

Coagulation

  • (INR) OR prothrombin time (PT)
  • Activated partial thromboplastin time (aPTT): ≤ 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants

Exclusion criteria

Exclusion Criteria:

  1. Has had major surgery, other than nephrectomy, within 4 weeks prior to randomization.

    Note: If participants received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.

  2. Has residual thrombus post nephrectomy in the vena renalis or vena cava.
  3. Has received prior therapy with an , anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
  4. Has received prior systemic anti-cancer therapy including agents within 4 weeks prior to randomization.

    Note: Participants must have recovered from all Adverse Events (AEs) due to previous therapies to ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible

  5. Has cardiovascular disease within 12 months from first dose of study intervention, including Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, undergone CABG or PTCA, or cardiac arrhythmia.

    Note: Medically controlled arrhythmia stable on medication is permitted.

  6. Has moderate to severe hepatic impairment ( B or C).
  7. Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require , and not have had radiation pneumonitis. A 1-week is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease.
  8. Has received a or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed.
  9. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.

    Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.

  10. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of study drug.
  11. Has a known additional that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, non-muscle invasive bladder cancer, prostate cancer pT2 or less, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
  12. Has known active and/or carcinomatous meningitis. Participants with previously surgically treated brain metastases may participate provided they are not radiological evidence of disease at the time of screening and without evidence of progression for at least 12 months by repeat imaging (note that the repeat imaging should be performed during study screening).
  13. Has severe (≥Grade 3) to pembrolizumab and/or any of its .
  14. Has active disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
  15. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  16. Has an active infection requiring systemic therapy.
  17. Has a known history of (HIV) infection.
  18. Has a known history of (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active virus (HCV, defined as HCV RNA is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
  19. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  20. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  21. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment.
  22. Has had an allogenic tissue/solid organ transplant.
  23. A who has a positive urine pregnancy test within 72 hours prior to randomization. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication.

Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    ARM A

    Pembrolizumab will be administered at flat dose of 400 mg IV every six weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RadioTherapy, RT) from day 21 of cycle 1 to day 42 of cycle 1.

    Drug: Pembrolizumab injection plus metastasis directed treatment (surgery or RT) · Other: Tumor resection or RT

  • Active comparator
    ARM B

    Local therapy alone (tumor resection or definitive RadioTherapy, RT) within 42 days from randomization.

    Other: Tumor resection or RT

Interventions

  • DrugPembrolizumab injection plus metastasis directed treatment (surgery or RT)

    Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks for a total of 9 cycles (one year of therapy) and metastasis directed treatment (surgery or RT) from day 21 of cycle 1 to day 42 of cycle 1

  • OtherTumor resection or RT

    Tumor resection or RT will be applied within 42 days from randomization.

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Relapsed Free Survival (RFS)

    The length of time from the randomization and the appearance of radiological progression of kidney cancer in patients who received pembrolizumab compared to those who did not

    Time frame: 24 months

Secondary outcomes

  1. Distant Relapsed Free Survival (Distant RFS)

    The length of time from the randomization to the appearance of distant metastases outside those treated with surgery or radiotherapy.

    Time frame: 24 months

  2. Overall Survival (OS)

    The time from the randomization to the patient's death or last contact in patients who received pembrolizumab compared to those who did not.

    Time frame: 24 months

  3. Safety Endpoint

    The overall incidence of adverse events in patients who received pembrolizumab compared to those who did not.

    Time frame: 24 months

  4. Local Progression Disease (Local PD)

    The overall incidence local progression in patients who received pembrolizumab plus RT compared to those who received RT alone

    Time frame: 24 months

07

Study locations

33 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Mar 2028, 60 months after the start.

Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's planned 60 months is below that.

Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Oct 2024 → Mar 2028 and completion Oct 2025 → Feb 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2022
First posted
Oct 13, 2022
StartActual
Mar 14, 2023
Primary completionEst.
Mar 2028was Oct 2024
CompletionEst.
Feb 2031was Oct 2025
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 21, 2026
Sites
32 sites added
Show 32 added (32 Italy)
  • A.O.U. Consorziale Policlinico di Bari · Bari, Italy
  • ASST Papa Giovanni XXIII · Bergamo, Italy
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola Malpighi · Bologna, Italy
  • ASST Spedali Civili di Brescia · Brescia, Italy
  • AOU Cagliari · Cagliari, Italy
  • ASST Cremona · Cremona, Italy
  • AOE Cannizzaro · Catania, Italy
  • AUO Careggi · Florence, Italy
  • IRCCS Policlinico San Martino · Genova, Italy
  • P.O. Vito Fazzi · Lecce, Italy
  • Azienda Usl Toscana Nord Ovest · Livorno, Italy
  • Azienda Sanitaria Territoriale di Macerata · Province of Macerata, Italy
  • Istituto Europeo di Oncologia · Milan, Italy
  • Fondazione IRCCS INT Milano · Milan, Italy
  • IRCCS Istituto Clinico Humanitas · Rozzano, Italy
  • AOU Policlinico di Modena · Modena, Italy
  • Istituto Oncologico Veneto - IRCCS · Padova, Italy
  • Casa di Cura La Maddalena s.p.a. · Palermo, Italy
  • Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia · Perugia, Italy
  • Azienda Ospedaliero-Universitaria Pisana · Pisa, Italy
  • Azienda Ospedaliero-Universitaria di Parma · Parma, Italy
  • AUSL/IRCCS di Reggio Emilia · Reggio Emilia, Italy
  • Istituti Fisioterapici Ospitalieri · Roma, Italy
  • Ospedale A. Tortora · Pagani, Italy
  • Fondazione del Piemonte per l'Oncologia - IRCCS · Candiolo, Italy
  • AOU S. Luigi Gonzaga · Orbassano, Italy
  • Azienda Ospedaliera S. Maria · Terni, Italy
  • Presidio Ospedaliero di Belcolle · Viterbo, Italy
  • AOUI Verona - Borgo Roma · Verona, Italy
  • AORN Antonio Cardarelli · Naples, Italy
  • …and 2 more on the registry record
Oct 21, 2026
Primary completion
Oct 2024→Mar 2028
Oct 21, 2026
Study completion
Oct 2025→Feb 2031
Oct 21, 2026
Enrollment
81 (estimated)→85 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Recruiting→Active, not recruiting
    32 sites added
    Show 32 added (32 Italy)
    • A.O.U. Consorziale Policlinico di Bari · Bari, Italy
    • ASST Papa Giovanni XXIII · Bergamo, Italy
    • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola Malpighi · Bologna, Italy
    • ASST Spedali Civili di Brescia · Brescia, Italy
    • AOU Cagliari · Cagliari, Italy
    • ASST Cremona · Cremona, Italy
    • AOE Cannizzaro · Catania, Italy
    • AUO Careggi · Florence, Italy
    • IRCCS Policlinico San Martino · Genova, Italy
    • P.O. Vito Fazzi · Lecce, Italy
    • Azienda Usl Toscana Nord Ovest · Livorno, Italy
    • Azienda Sanitaria Territoriale di Macerata · Province of Macerata, Italy
    • Istituto Europeo di Oncologia · Milan, Italy
    • Fondazione IRCCS INT Milano · Milan, Italy
    • IRCCS Istituto Clinico Humanitas · Rozzano, Italy
    • AOU Policlinico di Modena · Modena, Italy
    • Istituto Oncologico Veneto - IRCCS · Padova, Italy
    • Casa di Cura La Maddalena s.p.a. · Palermo, Italy
    • Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia · Perugia, Italy
    • Azienda Ospedaliero-Universitaria Pisana · Pisa, Italy
    • Azienda Ospedaliero-Universitaria di Parma · Parma, Italy
    • AUSL/IRCCS di Reggio Emilia · Reggio Emilia, Italy
    • Istituti Fisioterapici Ospitalieri · Roma, Italy
    • Ospedale A. Tortora · Pagani, Italy
    • Fondazione del Piemonte per l'Oncologia - IRCCS · Candiolo, Italy
    • AOU S. Luigi Gonzaga · Orbassano, Italy
    • Azienda Ospedaliera S. Maria · Terni, Italy
    • Presidio Ospedaliero di Belcolle · Viterbo, Italy
    • AOUI Verona - Borgo Roma · Verona, Italy
    • AORN Antonio Cardarelli · Naples, Italy
    • …and 2 more on the registry record
    Primary completion Oct 2024→Mar 2028
    Study completion Oct 2025→Feb 2031
    Enrollment 81 (estimated)→85 (actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05578664
Lead sponsor
Consorzio Oncotech
Responsible party
Sponsor
First posted
Oct 13, 2022
Start date
Mar 14, 2023
Primary completion
Mar 2028 (estimated)
Completion
Feb 2031 (estimated)
Last update
Oct 21, 2026

Study contacts

Roberto Iacovelli, MD, PhD
principal investigator · Fondazione Policlinico Universitario "A. Gemelli" IRCCS - UOC Oncologia Medica, Rome

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion